Northland Capmk Weighs in on Cardio Diagnostics Holdings, Inc.’s Q2 2023 Earnings (NASDAQ:CDIO)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIOGet Rating) – Analysts at Northland Capmk issued their Q2 2023 earnings per share estimates for shares of Cardio Diagnostics in a research report issued on Monday, May 22nd. Northland Capmk analyst C. Byrnes expects that the company will earn ($0.21) per share for the quarter. Northland Capmk also issued estimates for Cardio Diagnostics’ Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.75) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.55) EPS.

Separately, Northland Securities initiated coverage on shares of Cardio Diagnostics in a research note on Monday. They issued an “outperform” rating for the company.

Cardio Diagnostics Price Performance

Shares of Cardio Diagnostics stock opened at $1.38 on Wednesday. The business has a 50-day simple moving average of $2.81 and a 200-day simple moving average of $2.23. Cardio Diagnostics has a one year low of $0.80 and a one year high of $10.25.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CDIO. Bank of America Corp DE acquired a new stake in Cardio Diagnostics during the 1st quarter worth $59,000. Susquehanna International Group LLP acquired a new stake in shares of Cardio Diagnostics in the fourth quarter valued at approximately $26,000. State Street Corp purchased a new position in shares of Cardio Diagnostics during the first quarter worth approximately $163,000. Finally, Geode Capital Management LLC acquired a new position in shares of Cardio Diagnostics in the 1st quarter valued at $290,000. Hedge funds and other institutional investors own 77.29% of the company’s stock.

About Cardio Diagnostics

(Get Rating)

Cardio Diagnostics Holdings, Inc, a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.

Featured Stories

Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with's FREE daily email newsletter.